Sign in

CIK 0000939767

  • Large accelerated filer

EXELIXIS, INC.

Sign in to watch
Ticker
EXEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Jan 1
Incorporated
DE
Entity type
Operating
EIN
043257395
Phone
+1 650-837-7000
Business address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
Former names
EXELIXIS INC
  1. 4 Planned sale Director sold 19,205 shares at $24.01 ($461,112)
  2. 4 Grant or award EVP Prod Dev & Med Aff & CMO acquired 82,121 shares (grant or award)
  3. 4 Grant or award CSO/EVP Disc & Trans Research acquired 63,350 shares (grant or award)
  4. 4 Grant or award President and CEO acquired 241,670 shares (grant or award)
  5. 4 Grant or award EVP and CFO acquired 82,121 shares (grant or award)
  6. 4 Grant or award EVP, General Counsel & Sec acquired 63,350 shares (grant or award)
  7. 4 Open-market sale EVP, Commercial sold 47,020 shares at $21.45 ($1,008,579)
  8. 4 Open-market buy Director bought 190,000 shares at $20.70 ($3,932,734)
  9. 4 Shares withheld for taxes CSO/EVP Disc & Trans Research gave up 10,630 shares (to pay taxes)
  10. 4 Shares withheld for taxes President and CEO gave up 63,717 shares (to pay taxes)
  11. 4 Shares withheld for taxes EVP and CFO gave up 21,862 shares (to pay taxes)
  12. 4 Shares withheld for taxes EVP, General Counsel & Sec gave up 13,061 shares (to pay taxes)
  13. 4 Shares withheld for taxes EVP, Commercial gave up 13,613 shares (to pay taxes)
  14. 4 Shares withheld for taxes CSO/EVP Disc & Trans Research gave up 11,606 shares (to pay taxes)
  15. 4 Grant or award Director acquired 15,424 shares (grant or award)
  16. 4 Grant or award Director acquired 15,424 shares (grant or award)
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 4 Planned sale EVP, Commercial sold 64,149 shares at an average $23.16 ($1,485,853)
  20. 4 Planned sale EVP, General Counsel & Sec sold 25,000 shares at $23.01 ($575,250)

Page 9 of 73 · 1,458 filings